Pfizer announced that its innovative drug Talzenna (TALZENNA, generic name: talazoparib tosylate capsules) for the treatment of prostate cancer was approved by the National Medical Products Administration (NMPA) on October 29, 2024. It is used in combination with enzalutamide for adult patients with metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutations, becoming the only approved PARP inhibitor for the treatment of mCRPC with HRR gene mutations in China.
辉瑞靶向治疗创新药泰泽纳在华获批
Pfizer targeted therapy innovative drug Tazenna approved in China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated